AG˹ٷ

STOCK TITAN

[8-K] Vertex Pharmaceuticals Inc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Insider Sale: Executive Vice President & Head of Institutional Bank John Leto filed a Form 4 for The Bancorp Inc. (TBBK).

  • Transaction date: 08/01/2025
  • Securities: 50,000 common shares sold (Code “S�)
  • Average price: $60.3482 (price range $60.00-$61.56)
  • Post-sale holdings: 114,111 shares held directly; 3,540 shares held indirectly via 401(k)

No derivative trades were reported, and the filing was made by a single reporting person. Based on the stated amounts, the executive disposed of roughly 30% of his prior direct position (50,000 of ~164,111 shares), reducing—yet still leaving—a sizeable equity stake.

The absence of earnings or corporate event disclosures means this filing is purely a record of insider activity; investors often view sizable insider sales as a potential negative sentiment signal, though motives can vary (liquidity, diversification, preset plans).

Vendita da parte di un insider: Il Vice Presidente Esecutivo e Responsabile della Banca Istituzionale John Leto ha presentato un Modulo 4 per The Bancorp Inc. (TBBK).

  • Data della transazione: 01/08/2025
  • Titoli: 50.000 azioni ordinarie vendute (Codice “S�)
  • Prezzo medio: 60,3482 $ (intervallo di prezzo 60,00 $ - 61,56 $)
  • Detenzioni post-vendita: 114.111 azioni detenute direttamente; 3.540 azioni detenute indirettamente tramite 401(k)

Non sono state segnalate operazioni su derivati e la comunicazione è stata effettuata da un unico soggetto segnalante. In base agli importi indicati, il dirigente ha ceduto circa il 30% della sua posizione diretta precedente (50.000 su ~164.111 azioni), riducendo ma mantenendo comunque una partecipazione azionaria significativa.

La mancanza di comunicazioni su utili o eventi societari indica che questa segnalazione riguarda esclusivamente l’attività interna; gli investitori spesso interpretano vendite consistenti da parte di insider come un possibile segnale negativo, anche se le motivazioni possono variare (liquidità, diversificazione, piani prestabiliti).

Venta de insider: El Vicepresidente Ejecutivo y Jefe del Banco Institucional John Leto presentó un Formulario 4 para The Bancorp Inc. (TBBK).

  • Fecha de la transacción: 01/08/2025
  • Valores: 50.000 acciones comunes vendidas (Código “S�)
  • Precio promedio: $60,3482 (rango de precio $60,00-$61,56)
  • Posiciones tras la venta: 114.111 acciones en posesión directa; 3.540 acciones en posesión indirecta a través de 401(k)

No se reportaron operaciones con derivados y la presentación fue realizada por una sola persona informante. Según las cantidades indicadas, el ejecutivo vendió aproximadamente el 30% de su posición directa anterior (50.000 de ~164.111 acciones), reduciendo pero manteniendo una participación accionaria considerable.

La ausencia de anuncios de ganancias o eventos corporativos indica que esta presentación es únicamente un registro de actividad interna; los inversores suelen interpretar ventas significativas de insiders como una posible señal negativa, aunque las razones pueden variar (liquidez, diversificación, planes preestablecidos).

내부� 매도: The Bancorp Inc. (TBBK)� 부사장 � 기관은� 책임자인 John Leto가 Form 4� 제출했습니다.

  • 거래 날짜: 2025� 8� 1�
  • 증권: 보통� 50,000� 매도 (코드 “S�)
  • 평균 가�: $60.3482 (가� 범위 $60.00-$61.56)
  • 매도 � 보유 주식: 직접 보유 114,111�; 401(k)� 통한 간접 보유 3,540�

파생상품 거래� 보고되지 않았으며, 단일 보고자가 제출했습니다. 명시� 수량� 기준으로 경영진은 이전 직접 보유 주식 � 30% (� 164,111� � 50,000�)� 처분하여 보유 지분을 줄였지� 여전� 상당� 지분을 유지하고 있습니다.

수익 발표� 기업 이벤� 공지가 없으므� 이번 제출은 내부� 활동 기록� 불과합니�. 투자자들은 대규모 내부� 매도� 부정적 신호� 보는 경향� 있으�, 동기� 유동� 확보, 분산 투자, 사전 계획 � 다양� � 있습니다.

Vente d’initié : Le Vice-Président Exécutif et Responsable de la Banque Institutionnelle, John Leto, a déposé un formulaire 4 pour The Bancorp Inc. (TBBK).

  • Date de la transaction : 01/08/2025
  • Titres : 50 000 actions ordinaires vendues (Code « S »)
  • Prix moyen : 60,3482 $ (fourchette de prix 60,00 $ - 61,56 $)
  • Positions après vente : 114 111 actions détenues directement ; 3 540 actions détenues indirectement via un 401(k)

Aucune transaction sur dérivés n’a été signalée, et le dépôt a été effectué par une seule personne déclarant. D’après les montants indiqués, le dirigeant a cédé environ 30 % de sa position directe précédente (50 000 sur environ 164 111 actions), réduisant ainsi sa participation, tout en conservant une part importante du capital.

L’absence de communication sur les résultats ou événements d’entreprise signifie que ce dépôt est uniquement un enregistrement de l’activité des initiés ; les investisseurs considèrent souvent les ventes importantes d’initiés comme un signal potentiellement négatif, bien que les motivations puissent varier (liquidité, diversification, plans préétablis).

Insider-Verkauf: Executive Vice President und Leiter der Institutionellen Bank John Leto reichte ein Formular 4 für The Bancorp Inc. (TBBK) ein.

  • Transaktionsdatum: 01.08.2025
  • Wertpapiere: 50.000 Stammaktien verkauft (Code „S�)
  • Durchschnittspreis: 60,3482 $ (Preisspanne 60,00 $�61,56 $)
  • Bestände nach dem Verkauf: 114.111 Aktien direkt gehalten; 3.540 Aktien indirekt über 401(k) gehalten

Es wurden keine Derivatgeschäfte gemeldet und die Meldung erfolgte durch eine einzelne meldende Person. Basierend auf den angegebenen Mengen veräußerte der Executive etwa 30 % seiner vorherigen direkten Position (50.000 von ca. 164.111 Aktien), wodurch er seine Beteiligung verringerte, aber weiterhin eine bedeutende Aktienposition hält.

Das Fehlen von Gewinn- oder Unternehmensereignis-Mitteilungen bedeutet, dass diese Meldung ausschließlich eine Aufzeichnung der Insider-Aktivität ist; Investoren sehen umfangreiche Insider-Verkäufe oft als potenzielles negatives Signal, wobei die Motive variieren können (Liquidität, Diversifikation, vorab festgelegte Pläne).

Positive
  • Executive retains 114,111 direct shares, sustaining a meaningful equity alignment with shareholders.
Negative
  • Sale of 50,000 shares (~30% of prior direct holdings) by EVP may be interpreted as a bearish sentiment signal.

Insights

TL;DR: EVP sells 50k shares (~30% stake); modestly bearish insider signal, no related corporate news.

Materiality: While Form 4s don’t directly affect fundamentals, size and rank matter. Leto’s sale (~$3 m) is significant relative to his ownership, signalling some near-term profit-taking at 52-week highs. No 10b5-1 box is marked, suggesting it may not be a pre-scheduled trade. He still controls 117k shares, so alignment remains, but directionally this tilts negative for sentiment-driven investors. Fundamentals unchanged; impact rated negative but not transformational.

TL;DR: Large discretionary sale by key officer; governance impact limited, watch for pattern.

From a governance lens, isolated insider sales are common. The form indicates proper, timely reporting with remaining meaningful ownership, mitigating concerns of total exit. However, a 30% trim outside a disclosed 10b5-1 plan warrants monitoring for recurring sales that could erode perceived alignment. Overall influence on governance risk profile is neutral today, but trends matter.

Vendita da parte di un insider: Il Vice Presidente Esecutivo e Responsabile della Banca Istituzionale John Leto ha presentato un Modulo 4 per The Bancorp Inc. (TBBK).

  • Data della transazione: 01/08/2025
  • Titoli: 50.000 azioni ordinarie vendute (Codice “S�)
  • Prezzo medio: 60,3482 $ (intervallo di prezzo 60,00 $ - 61,56 $)
  • Detenzioni post-vendita: 114.111 azioni detenute direttamente; 3.540 azioni detenute indirettamente tramite 401(k)

Non sono state segnalate operazioni su derivati e la comunicazione è stata effettuata da un unico soggetto segnalante. In base agli importi indicati, il dirigente ha ceduto circa il 30% della sua posizione diretta precedente (50.000 su ~164.111 azioni), riducendo ma mantenendo comunque una partecipazione azionaria significativa.

La mancanza di comunicazioni su utili o eventi societari indica che questa segnalazione riguarda esclusivamente l’attività interna; gli investitori spesso interpretano vendite consistenti da parte di insider come un possibile segnale negativo, anche se le motivazioni possono variare (liquidità, diversificazione, piani prestabiliti).

Venta de insider: El Vicepresidente Ejecutivo y Jefe del Banco Institucional John Leto presentó un Formulario 4 para The Bancorp Inc. (TBBK).

  • Fecha de la transacción: 01/08/2025
  • Valores: 50.000 acciones comunes vendidas (Código “S�)
  • Precio promedio: $60,3482 (rango de precio $60,00-$61,56)
  • Posiciones tras la venta: 114.111 acciones en posesión directa; 3.540 acciones en posesión indirecta a través de 401(k)

No se reportaron operaciones con derivados y la presentación fue realizada por una sola persona informante. Según las cantidades indicadas, el ejecutivo vendió aproximadamente el 30% de su posición directa anterior (50.000 de ~164.111 acciones), reduciendo pero manteniendo una participación accionaria considerable.

La ausencia de anuncios de ganancias o eventos corporativos indica que esta presentación es únicamente un registro de actividad interna; los inversores suelen interpretar ventas significativas de insiders como una posible señal negativa, aunque las razones pueden variar (liquidez, diversificación, planes preestablecidos).

내부� 매도: The Bancorp Inc. (TBBK)� 부사장 � 기관은� 책임자인 John Leto가 Form 4� 제출했습니다.

  • 거래 날짜: 2025� 8� 1�
  • 증권: 보통� 50,000� 매도 (코드 “S�)
  • 평균 가�: $60.3482 (가� 범위 $60.00-$61.56)
  • 매도 � 보유 주식: 직접 보유 114,111�; 401(k)� 통한 간접 보유 3,540�

파생상품 거래� 보고되지 않았으며, 단일 보고자가 제출했습니다. 명시� 수량� 기준으로 경영진은 이전 직접 보유 주식 � 30% (� 164,111� � 50,000�)� 처분하여 보유 지분을 줄였지� 여전� 상당� 지분을 유지하고 있습니다.

수익 발표� 기업 이벤� 공지가 없으므� 이번 제출은 내부� 활동 기록� 불과합니�. 투자자들은 대규모 내부� 매도� 부정적 신호� 보는 경향� 있으�, 동기� 유동� 확보, 분산 투자, 사전 계획 � 다양� � 있습니다.

Vente d’initié : Le Vice-Président Exécutif et Responsable de la Banque Institutionnelle, John Leto, a déposé un formulaire 4 pour The Bancorp Inc. (TBBK).

  • Date de la transaction : 01/08/2025
  • Titres : 50 000 actions ordinaires vendues (Code « S »)
  • Prix moyen : 60,3482 $ (fourchette de prix 60,00 $ - 61,56 $)
  • Positions après vente : 114 111 actions détenues directement ; 3 540 actions détenues indirectement via un 401(k)

Aucune transaction sur dérivés n’a été signalée, et le dépôt a été effectué par une seule personne déclarant. D’après les montants indiqués, le dirigeant a cédé environ 30 % de sa position directe précédente (50 000 sur environ 164 111 actions), réduisant ainsi sa participation, tout en conservant une part importante du capital.

L’absence de communication sur les résultats ou événements d’entreprise signifie que ce dépôt est uniquement un enregistrement de l’activité des initiés ; les investisseurs considèrent souvent les ventes importantes d’initiés comme un signal potentiellement négatif, bien que les motivations puissent varier (liquidité, diversification, plans préétablis).

Insider-Verkauf: Executive Vice President und Leiter der Institutionellen Bank John Leto reichte ein Formular 4 für The Bancorp Inc. (TBBK) ein.

  • Transaktionsdatum: 01.08.2025
  • Wertpapiere: 50.000 Stammaktien verkauft (Code „S�)
  • Durchschnittspreis: 60,3482 $ (Preisspanne 60,00 $�61,56 $)
  • Bestände nach dem Verkauf: 114.111 Aktien direkt gehalten; 3.540 Aktien indirekt über 401(k) gehalten

Es wurden keine Derivatgeschäfte gemeldet und die Meldung erfolgte durch eine einzelne meldende Person. Basierend auf den angegebenen Mengen veräußerte der Executive etwa 30 % seiner vorherigen direkten Position (50.000 von ca. 164.111 Aktien), wodurch er seine Beteiligung verringerte, aber weiterhin eine bedeutende Aktienposition hält.

Das Fehlen von Gewinn- oder Unternehmensereignis-Mitteilungen bedeutet, dass diese Meldung ausschließlich eine Aufzeichnung der Insider-Aktivität ist; Investoren sehen umfangreiche Insider-Verkäufe oft als potenzielles negatives Signal, wobei die Motive variieren können (Liquidität, Diversifikation, vorab festgelegte Pläne).

0000875320VERTEX PHARMACEUTICALS INC / MAfalse00008753202025-08-042025-08-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 4, 2025

Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
Massachusetts
000-19319
04-3039129
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
50 Northern Avenue
Boston, Massachusetts 02210
(Address of principal executive offices) (Zip Code)

(617) 341-6100
(Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02.  Results of Operations and Financial Condition.
     
On August 4, 2025, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and six months ended June 30, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 4, 2025, the Company announced the retirement of David Altshuler, Executive Vice President and Chief Scientific Officer, effective August 1, 2026.
Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

ExhibitDescription of Document
99.1
Press Release Dated August 4, 2025.
104Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)
Date: August 4, 2025
/s/ Jonathan Biller
Jonathan Biller
Executive Vice President, Chief Legal Officer

FAQ

How many TBBK shares did EVP John Leto sell?

He disposed of 50,000 common shares on 08/01/2025.

At what price were the TBBK shares sold?

The weighted-average sale price was $60.3482, within a $60.00�$61.56 range.

What is John Leto's remaining stake in The Bancorp Inc.?

After the transaction he holds 114,111 shares directly and 3,540 shares indirectly through a 401(k).

Were any derivative securities involved in this Form 4?

No, no derivative transactions were reported in Table II.

Was the sale under a Rule 10b5-1 trading plan?

The filing does not indicate that the transaction was executed under a 10b5-1 plan.
Vertex Pharmaceuticals Inc

NASDAQ:VRTX

VRTX Rankings

VRTX Latest News

VRTX Latest SEC Filings

VRTX Stock Data

118.67B
256.18M
0.14%
98.15%
1.63%
Biotechnology
Pharmaceutical Preparations
United States
BOSTON